Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
On Monday, BTIG reaffirmed its positive stance on Vaxcyte (NASDAQ:PCVX) shares, maintaining a Buy rating and a price target of $160.00. The ~$10 billion market cap company enjoys strong Wall Street support, with analyst targets ranging from $135 to $163. According to InvestingPro data, Vaxcyte maintains a highly favorable analyst consensus rating of 1.2, indicating strong buy recommendations across the board. The firm’s focus is on the upcoming interim data from the Phase 2 trial of VAX-24, Vaxcyte’s pneumococcal vaccine candidate for infants. Despite not expecting data to be revealed in the quarterly earnings call on Tuesday, analysts consider this trial a significant evaluation of Vaxcyte’s platform. InvestingPro analysis shows the company maintains a FAIR overall financial health score, with particularly strong scores in price momentum and cash flow management. Subscribers can access 6 additional ProTips and comprehensive financial metrics to better evaluate Vaxcyte’s investment potential.
Analysts anticipate that VAX-24 may outperform existing vaccines by missing fewer serotypes after the initial three shots given to children. The performance after three doses is particularly important because it indicates the level of protection children have before receiving a fourth booster shot. Comparatively, PREVNAR20, a currently approved vaccine, missed on six serotypes after three doses, whereas VAX-24 is expected to miss on two at most, with the potential for zero misses.
Vaxcyte’s management has indicated that the serotype ratio in VAX-31 for infants mirrors that of the adult formulation, suggesting a strong translation of immunogenicity from adults to infants. Minor adjustments in the serotype ratios in VAX-31 aim to enhance the vaccine’s efficacy by leveraging the immune response from stronger serotypes.
Looking ahead, Vaxcyte plans to initiate a Phase 3 non-inferiority study in adults by mid-2025, with topline data anticipated in 2026 and a potential market entry in 2027. The company’s strong financial position is evident through its robust current ratio of 17.88 and minimal debt-to-equity ratio of 0.01, suggesting ample resources to fund its clinical development programs. The company’s VAX-31 candidate has demonstrated high immunogenicity and a favorable safety profile, positioning it as a strong contender for the adult pneumococcal vaccine market upon approval.
The recent recommendation by the Advisory Committee on Immunization Practices (ACIP) to lower the age recommendation for pneumococcal conjugate vaccines to 50 years and older could significantly expand the total addressable market for VAX-31.
Final data for the first three doses of VAX-24 are expected by the end of the first quarter of 2025, with results from the booster dose expected by the end of the year. Additionally, topline results from the Phase 2 study of VAX-31 in infants are projected for mid-2026, followed by booster-dose immunogenicity data nine months later.
In other recent news, Vaxcyte has announced the progression to the final stage of its Phase 2 study for VAX-31, a pneumococcal conjugate vaccine candidate. This stage will further evaluate the vaccine’s safety, tolerability, and immunogenicity in healthy infants, with the company planning to release topline data from the primary immunization series in mid-2026. Additionally, Goldman Sachs has initiated coverage on Vaxcyte with a Buy rating, citing strong clinical data for its lead programs as a positive indicator for the company’s future. The firm has set a price target of $135.00, highlighting the potential of VAX-31 and other pipeline assets to drive long-term growth. Vaxcyte’s proprietary technology platform has been instrumental in overcoming traditional challenges in vaccine development, positioning the company as a significant player in the pneumococcal vaccine market. The company’s efforts to address next-generation vaccine challenges have been well-received, with Goldman Sachs noting the de-risking of VAX-31 as a key factor in its regulatory and commercial potential. These developments underscore Vaxcyte’s commitment to advancing its vaccine pipeline and expanding its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.